Portfolio Lab

Myriad Genetics Inc

  • Stock
  • Ticker MYGN
  • ISIN US62855J1043
  • Nasdaq

Health care · Diagnostics · USA

$5.46 −1.44%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Myriad Genetics Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

MYGNGlobal equities (VT)

$10,000 grew to $3,182. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −94.3% in 07/2026, measured from the peak in 09/2018. The old peak has not been reached again yet.

1-year return
−20.9%
5-year return p.a.
−27.9%
10-year return p.a.
−10.8%
Volatility p.a.
64.4%
Largest decline
−94.3%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue211196213206210200191203
Gross profit151134152144147138127138
Operating income-39-29-329-23-5.7-31-39-40
EBITDA-24-15-324-196.9-18-34-35
Net income-43-0.1-331-27-7.9-34-43-44
Earnings per share-0.470.00-3.57-0.29-0.07-0.36-0.46-0.46
Balance sheet
Total assets1,0281,006677728707674639609
Liabilities327301289355339336335340
Equity701705388373368337304269
Cash1029274145150124115107
Long-term debt40590.0120120120121121
Cash flow
Operating cash flow6.6-16-142111-16-8.3-6.5
Free cash flow6.6-16-142111-16-8.3-6.5

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +106.1%, weakest 2025 at −55.1%. 3 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026−$0.46
31 Jul 2026−$0.46
6 May 2026−$0.36
24 Feb 2026−$0.07
4 Nov 2025−$0.29
6 Aug 2025−$3.57
7 May 2025$0.00
28 Feb 2025−$0.47
8 Nov 2024−$0.24
7 Aug 2024−$0.41
8 May 2024−$0.29
28 Feb 2024−$0.34

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€475m
Market cap in trading currency
$524m
Enterprise value
$538m
P/E
–
P/S
0.65
P/B
1.95
EV/Sales
0.67
EV/EBITDA
–
Earnings yield
–
FCF yield
-3.8%

Results (last four quarters)

Revenue
$804m
Gross profit
$549m
EBITDA
−$80.4m
Net income
−$129m
Earnings per share
−$1.35
Revenue per share
$8.38
Revenue growth
−1.5%
Earnings growth
–

Profitability

Gross margin
68.3%
Operating margin
-14.3%
Net margin
-16.1%
Return on equity
-40.2%
Return on assets
-21.2%

Balance sheet and cash flow

Cash
$107m
Cash per share
$1.12
Financial debt
$121m
Debt/equity %
45
Current ratio
1.98
Book value per share
$2.80
Operating cash flow
−$19.9m
Free cash flow
−$19.9m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
95.9m
Volume
1.25m
Avg. volume 3 months
2.32m
Relative volume
0.5

Price and technicals

Price
$5.46
1 day
−1.4%
52-week high
$7.91
52-week low
$2.86
Distance to 52-week high
−31.0%
Distance to 52-week low
+90.9%
Distance to 50-day line
+9.7%
Distance to 200-day line
+18.4%
RSI (14)
49
Volatility 1M
54.3%

Performance

1 week
−3.5%
1 month
−5.2%
3 months
+79.0%
6 months
+42.9%
YTD
−11.2%
1 year
−15.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has MYGN performed since 11/2016?

$10,000 grew to $3,182 by 20 Nov 2026, which is −10.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is MYGN?

Volatility was 64.4% per year, measured on monthly returns. The largest decline from a peak was −94.3%, with the low in 07/2026.

How does MYGN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, MYGN returned −10.8% at 64.4%. The correlation of monthly returns was 0.38; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Myriad Genetics Inc (MYGN): Return and risk | Portfolio Lab